Diazoxide - Advancell/Neurotec

Drug Profile

Diazoxide - Advancell/Neurotec

Alternative Names: ATH-0012; ATH-012; NT-KO-003

Latest Information Update: 03 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advancell; Neurotec Pharma
  • Class Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Diagnostic agents; Peripheral vasodilators; Small molecules
  • Mechanism of Action Immunomodulators; Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple sclerosis
  • Preclinical Amyotrophic lateral sclerosis
  • Research CNS trauma

Most Recent Events

  • 03 Aug 2015 Phase II development for Multiple sclerosis is ongoing
  • 27 May 2014 Early research in CNS trauma (diagnosis) and Diagnostic tests in Spain (unspecified route)
  • 27 May 2014 Preclinical trials in Amyotrophic lateral sclerosis in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top